$10 Copy of Gilead’s Blockbuster Sovaldi Appears in Bangladesh - (Bloomberg via NewsPoints Desk)

  • An unlicensed generic version of Gilead Sciences' hepatitis C drug Sovaldi is now available in Bangladesh, and could also make its way elsewhere where the company does not have patents, reported Bloomberg.
  • Incepta Pharmaceuticals does not hold a license from Gilead and its version was launched last month, according to managing director Abdul Muktadir, while the company also aims to market the drug overseas, including to parts of Southeast Asia and Africa.
  • Gilead stated that it is "aware of unauthorized generic versions of [Sovaldi] being offered in the marketplace," adding that "we're focused on enabling our eleven Indian generic partners to launch their authorized generic versions as soon as possible."
  • In the US, Sovaldi costs $84 000 for a 12-week course of treatment, while Incepta's price for its generic version is about $900 for 12 weeks, the same price at which Gilead will offer its branded version of the drug in India.
  • Meanwhile, the WHO is in talks with Incepta along with a "handful" of companies in India and Egypt on pre-qualification of Sovaldi generics, according to Peter Beyer, senior advisor in the WHO's department of essential medicines and health products.
  • Incepta is currently preparing quality and dissolution studies on its version of Sovaldi to submit in support of its international applications, Muktadir said.

To read more NewsPoints articles, click here.